Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS), has announced the appointment of Glenn C. Yiu, M.D. Ph.D. as a new member of its Scientific Advisory Board (SAB). The SAB consists of renowned retinal physicians within the industry, providing valuable medical and scientific expertise for the company’s research and development programs.
Dr. Yiu currently holds the position of Professor of Ophthalmology at the University of California, Davis. His extensive knowledge and experience in ophthalmology make him a valuable addition to Clearside Biomedical’s SAB. He will bring valuable insights and contribute to the advancement of the company’s innovative therapeutic delivery methods.
Clearside Biomedical has been revolutionizing the way therapies are delivered to the back of the eye through its unique suprachoroidal space approach. The SCS allows for targeted delivery and increased efficacy of treatments for various retinal diseases. By including experts like Dr. Yiu on their SAB, Clearside Biomedical aims to further develop and enhance their research and development efforts.
In recent financial news, Clearside Biomedical’s financial report for the 12 months ending in the third quarter of 2023 showed a cumulative net loss of $-37 million. This resulted in a negative return on investment (ROI) of -101.04%. Although this financial data highlights a challenging period for the company, the appointment of Dr. Yiu to the SAB further underlines Clearside Biomedical’s commitment to innovation and growth.
Overall, the addition of Dr. Yiu to Clearside Biomedical’s Scientific Advisory Board is a significant development for the company. With his expertise and contributions, the company aims to advance its research and development programs, ultimately improving the delivery of therapies to treat various retinal diseases.
Comments